SCHEMBL2949261

SCHEMBL2949261

Cc1cccc(Nc2c(C#N)sc3c2ccc(=O)n3C2CC2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.39
PRKDC P78527 2/20 0.37
PIK3CA P42336 1/20 0.37
MAPT P10636 2/20 0.36
HAVCR2 Q8TDQ0 1/20 0.35
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
FER P16591 3/20 0.33
KMT2A Q03164 2/20 0.33
IMPDH2 P12268 1/20 0.33
NPSR1 Q6W5P4 2/20 0.33
DRD4 P21917 2/20 0.33
MEN1 O00255 1/20 0.33
PSMD14 O00487 1/20 0.33
POLB P06746 1/20 0.33
MMP2 P08253 1/20 0.33
PTPN7 P35236 1/20 0.33
PPARG P37231 1/20 0.33
DUSP3 P51452 1/20 0.33
PTPN5 P54829 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2952695 0.84 LMNA (0.36) PRKDCPOLB
SCHEMBL2958242 0.83 IDO1 (0.37) IDO1MAPTHAVCR2RAB9AFER
SCHEMBL2956929 0.81 RAB9A (0.39) PRKDCPIK3CAMAPTRAB9ANPC1
SCHEMBL2947088 0.80 IDO1 (0.39) IDO1MAPTHAVCR2RAB9ANPC1
SCHEMBL2958784 0.80 IDO1 (0.39) IDO1MAPTHAVCR2RAB9ANPC1
SCHEMBL2952051 0.79 IDO1 (0.38) IDO1MAPTHAVCR2RAB9ANPC1
SCHEMBL2959756 0.78 IDO1 (0.37) IDO1MAPTHAVCR2RAB9AKMT2A
SCHEMBL2961083 0.77 MAPT (0.39) IDO1MAPTHAVCR2RAB9ANPC1
SCHEMBL6102447 0.77 CSF1R (0.35) POLB
SCHEMBL2947080 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7482452-B2 Process for preparing 3-aminothienopyridone derivatives CELLTECH R&D LIMITED (GB) 2009-01-27 US disclosed
EP-1638980-B1 PROCESS FOR PREPARING 3-AMINOTHIENOPYRIDONE DERIVATIVES UCB PHARMA SA (BE) 2008-11-05 EP disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20070191608-A1 Process for preparing 3-aminothienopyridone derivatives CELLTECH R&D LIMITED (GB) 2007-08-16 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191608-A1 Process for preparing 3-aminothienopyridone derivatives MAPK3, MAP3K6, MAP4K1 IDO1 1258/4885PRKDC 297/4885PIK3CA 387/4885
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK IDO1 100/4885PRKDC 665/4885PIK3CA 2154/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 IDO1 215/4885PRKDC 1268/4885PIK3CA 1954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.